Open AccessExosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
Author(s) -
Lin Yao,
Wu Jiahua,
Gu Weihuai,
Huang Yulei,
Tong Zhongchun,
Huang Lijia,
Tan Jiali
Publication year - 2018
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201700611
Subject(s) - crispr , microvesicles , exosome , cas9 , liposome , genome editing , gene delivery , mesenchymal stem cell , transfection , in vivo , plasmid , genetic enhancement , biology , microbiology and biotechnology , chemistry , computational biology , gene , nanotechnology , microrna , materials science , genetics
Targeted delivery of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) system to the receptor cells is essential for in vivo gene editing. Exosomes are intensively studied as a promising targeted drug delivery carrier recently, while limited by their low efficiency in encapsulating of large nucleic acids. Here, a kind of hybrid exosomes with liposomes is developed via simple incubation. Different from the original exosomes, the resultant hybrid nanoparticles efficiently encapsulate large plasmids, including the CRISPR–Cas9 expression vectors, similarly as the liposomes. Moreover, the resultant hybrid nanoparticles can be endocytosed by and express the encapsulated genes in the mesenchymal stem cells (MSCs), which cannot be transfected by the liposome alone. Taken together, the exosome–liposome hybrid nanoparticles can deliver CRISPR–Cas9 system in MSCs and thus be promising in in vivo gene manipulation.